Literature DB >> 26193965

Discordance of Histologic Grade Between Primary and Metastatic Neuroendocrine Carcinomas.

Taiwo Adesoye1, Marie A Daleo2, Agnes G Loeffler2, Emily R Winslow1, Sharon M Weber1,3, Clifford S Cho4,5.   

Abstract

BACKGROUND: The prognosis and management of neuroendocrine carcinoma are largely driven by histologic grade as assessed by mitotic activity. The authors reviewed their institutional experience to determine whether the histologic grade of neuroendocrine carcinoma can differ between primary and metastatic tumors.
METHODS: This study examined patients who underwent operative resection of both primary and metastatic foci of neuroendocrine carcinoma. Resected tumors were independently reviewed and categorized as low, intermediate, or high grade as determined by mitotic count.
RESULTS: The authors identified 20 patients with metastatic neuroendocrine carcinoma treated at their institution between 1997 and 2013 for whom complete pathologic review of primary and metastatic tumors was possible. Primary lesions were found in the small intestine (n = 12), pancreas (n = 7), ampulla (n = 1), stomach (n = 1), and rectum (n = 1). The timing of hepatic metastasis was synchronous in 15 cases and metachronous in 5 cases. The histologic grade was concordant between primary and metastatic tumors in 9 cases and discordant in 11 cases. Among the discordant cases, 7 had a higher metastatic grade than primary grade, and 4 had a lower metastatic grade than primary grade. Metachronous presentation was associated with a higher likelihood of grade discordance (p = 0.03). The histologic grade of all metachronous metastases differed from that of the primary tumors.
CONCLUSION: There is a high prevalence of histologic grade discordance between primary and metastatic foci of neuroendocrine carcinoma, particularly among patients with a metachronous metastatic presentation. Given the importance of histologic grade in disease prognostication and treatment planning, this finding may be informative for the management of patients with metastatic neuroendocrine carcinoma.

Entities:  

Mesh:

Year:  2015        PMID: 26193965      PMCID: PMC4859783          DOI: 10.1245/s10434-015-4733-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  15 in total

1.  Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.

Authors:  Zhaohai Yang; Laura H Tang; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

2.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

3.  Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms.

Authors:  Clifford S Cho; Daniel M Labow; Laura Tang; David S Klimstra; Agnes G Loeffler; Glen E Leverson; Yuman Fong; William R Jarnagin; Michael I D'Angelica; Sharon M Weber; Leslie H Blumgart; Ronald P Dematteo
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

Review 4.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  A simplified prognostic system for resected pancreatic neuroendocrine neoplasms.

Authors:  Nikiforos Ballian; Agnes G Loeffler; Victoria Rajamanickam; Peter A Norstedt; Sharon M Weber; Clifford S Cho
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

6.  Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.

Authors:  S Singh; J Hallet; C Rowsell; C H L Law
Journal:  Eur J Surg Oncol       Date:  2014-07-24       Impact factor: 4.424

7.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Authors:  Ulrich-Frank Pape; Henning Jann; Jacqueline Müller-Nordhorn; Angelina Bockelbrink; Uta Berndt; Stefan N Willich; Martin Koch; Christoph Röcken; Guido Rindi; Bertram Wiedenmann
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

8.  Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.

Authors:  H C Miller; P Drymousis; R Flora; R Goldin; D Spalding; A Frilling
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

9.  Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Aejaz Nasir; Domenico Coppola; Mark Wick; Larry Kvols
Journal:  Hum Pathol       Date:  2009-04-14       Impact factor: 3.466

Review 10.  Prognostic factors in gastrointestinal endocrine tumors.

Authors:  Guido Rindi; Tiziana D'Adda; Elisabetta Froio; Giovanni Fellegara; Cesare Bordi
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

View more
  11 in total

1.  Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival.

Authors:  Ji Hye Min; Tae Wook Kang; Young Kon Kim; Seong Hyun Kim; Kyung Sook Shin; Jeong Eun Lee; Sang Yun Ha; Insuk Sohn
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

2.  Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.

Authors:  Akira Toriihara; Lucia Baratto; Tomomi Nobashi; Sonya Park; Negin Hatami; Guido Davidzon; Pamela L Kunz; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-27       Impact factor: 9.236

Review 3.  Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Authors:  Sven-Petter Haugvik; Daniel Kaemmerer; Sebastien Gaujoux; Knut Jørgen Labori; Caroline Sophie Verbeke; Ivar Prydz Gladhaug
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

4.  The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.

Authors:  Jiangyuan Yu; Nan Li; Jie Li; Ming Lu; Jeffrey P Leal; Huangying Tan; Hua Su; Yang Fan; Yan Zhang; Wei Zhao; Hua Zhu; Martin G Pomper; Yun Zhou; Zhi Yang
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 5.  Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors:  Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

6.  Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors.

Authors:  Amit Tirosh; Georgios Z Papadakis; Corina Millo; Dima Hammoud; Samira M Sadowski; Peter Herscovitch; Karel Pacak; Stephen J Marx; Lily Yang; Pavel Nockel; Jasmine Shell; Patience Green; Xavier M Keutgen; Dhaval Patel; Naris Nilubol; Electron Kebebew
Journal:  Gastroenterology       Date:  2017-11-16       Impact factor: 22.682

7.  DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.

Authors:  Etay Ziv; Samuel L Rice; John Filtes; Hooman Yarmohammadi; F Edward Boas; Joseph P Erinjeri; Elena Nadia Petre; Lynn A Brody; Karen T Brown; Anne M Covey; George I Getrajdman; Majid Maybody; Nitya Raj; Constantinos T Sofocleous; Stephen B Solomon; Diane Reidy-Lagunes
Journal:  J Vasc Interv Radiol       Date:  2018-10-19       Impact factor: 3.464

Review 8.  A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.

Authors:  Jiayun M Fang; Jiaqi Shi
Journal:  Arch Pathol Lab Med       Date:  2019-09-11       Impact factor: 5.534

9.  Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask.

Authors:  Manuela Albertelli; Federica Grillo; Fabio Lo Calzo; Giulia Puliani; Carmen Rainone; Annamaria Anita Livia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

10.  Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade.

Authors:  Alessandra Pulvirenti; Rikiya Yamashita; Jayasree Chakraborty; Natally Horvat; Kenneth Seier; Caitlin A McIntyre; Sharon A Lawrence; Abhishek Midya; Maura A Koszalka; Mithat Gonen; David S Klimstra; Diane L Reidy; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  JCO Clin Cancer Inform       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.